about
Update on therapeutic options in Waldenström macroglobulinemiaThe role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.Building a tiered approach to in vitro predictive toxicity screening: a focus on assays with in vivo relevance.Activation of the unfolded protein response is associated with impaired granulopoiesis in transgenic mice expressing mutant Elane.Morphoproteomics identifies constitutive activation of the mTORC2/Akt and NF-κB pathways and expressions of IGF-1R, Sirt1, COX-2, and FASN in peripheral T-cell lymphomas: pathogenetic implications and therapeutic options.Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterizationInvestigating the mechanism of hepatocellular carcinoma progression by constructing genetic and epigenetic networks using NGS data identification and big database mining methodClinical Trials of Antiangiogenesis Therapy on Gastric Cancer.The diverse and complex roles of NF-κB subunits in cancer.Implications of endoplasmic reticulum stress, the unfolded protein response and apoptosis for molecular cancer therapy. Part II: targeting cell cycle events, caspases, NF-κB and the proteasome.Bortezomib-induced peripheral neurotoxicity: an update.Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics.Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner.TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species.Orthopoxviruses require a functional ubiquitin-proteasome system for productive replication.Novel proteasome inhibitor delanzomib sensitizes cervical cancer cells to doxorubicin-induced apoptosis via stabilizing tumor suppressor proteins in the p53 pathway.A phase II trial of tamoxifen and bortezomib in patients with recurrent malignant gliomas.
P2860
Q28304195-85E1F9AF-E7E4-483E-AA4E-6152BDDBDE62Q30248842-7F1B66B9-6394-43C3-9733-344A7A0F0638Q34015408-3F4E0370-3D47-4C8B-AAEB-A569B93EC67FQ34773996-F77A5BA5-A391-4751-B9C2-9571F1EFF801Q35038458-9E7E3B4F-82C0-470F-B732-D543240CBA6DQ35051496-3EBC5F0F-E24D-4C85-BF35-70EC01245EFAQ36185043-D2BF9AF4-FDBC-48F8-8953-9BD4DFF88F9CQ37498953-DAB82FAE-D26C-474D-BD15-DA4338D750DBQ37976939-A9DEEA08-2DD7-45A3-BB64-54F41F6E0E5EQ38088360-048D882B-DDD2-430E-AC68-FFAC05F660A3Q38234733-0B183F3C-99E8-4835-B8A4-8A1DAF28B7E3Q38664595-BC1DEA45-F1A1-489B-8E85-044B788BB658Q39156092-3FDEC4EE-F8DF-43B7-BD04-AD5D8318C442Q39778764-B5D122E5-8E96-4F47-89CF-C04A92B1B54AQ42122542-2298EF9E-AFD6-446A-BBD8-C4B4B90C1891Q48522982-328EDEEE-E83E-422C-B1C4-441207C5B754Q52151078-E2FD9680-15EF-44B1-84EF-767AED4C884C
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Bortezomib in the treatment of cancer.
@en
Bortezomib in the treatment of cancer.
@nl
type
label
Bortezomib in the treatment of cancer.
@en
Bortezomib in the treatment of cancer.
@nl
prefLabel
Bortezomib in the treatment of cancer.
@en
Bortezomib in the treatment of cancer.
@nl
P1476
Bortezomib in the treatment of cancer.
@en
P2093
Aldo M Roccaro
Angelo Vacca
P304
P356
10.2174/157489206778776925
P577
2006-11-01T00:00:00Z